📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-05 18:19
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
10 announcements match the current filters (relevance ≥ 5).
₹100 Cr Rights Issue Approved by Sarda Proteins; Director Resigns
Sarda Proteins has approved a significant fundraise through a Rights Issue of equity shares for an amount not exceeding ₹100 crore. This proposed issue size is substantial, representing approximately 116% of the company's reported net worth of ₹86 crore. Simultaneously, the company announced the resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026. A Rights Issue Committee has been formed to oversee the process, including the filing of the Draft Letter of Offer with SEBI.
Confidence: HIGH
What changedThe company has initiated a major capital raising process and experienced a change in its board of directors.
Why it mattersA ₹100 crore fundraise is transformative for a company with a quarterly revenue of just ₹0.65 crore (Mar 2026), suggesting a potential major expansion or shift in business scale.
Rights Issue Size: ₹100 CroreNet Worth: ₹86 CrFundraise vs Net Worth: ~116%Mar 2026 Revenue: ₹0.65 CrDirector Resignation Date: August 05, 2026
📅 Short termThe stock may experience volatility as the market digests the scale of the rights issue and awaits pricing and ratio details.
📈 Long termIf the ₹100 crore is deployed effectively into revenue-generating assets, it could structurally re-rate the company from its current low-revenue base.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution
- Execution risk for a fundraise larger than current net worth
- Low current revenue base relative to fundraise size
Key Highlights
Approved a Rights Issue of equity shares for a total amount not exceeding ₹100 crore
Proposed fundraise of ₹100 crore exceeds the company's current net worth of ₹86 crore
Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
Board meeting concluded within 45 minutes (4:30 PM to 5:15 PM) to approve these measures
Company to separately intimate the Record Date upon finalization of the Draft Letter of Offer
👀 What to Watch
Investors should closely monitor the Draft Letter of Offer (DLOF) to understand the specific utilization of the ₹100 crore proceeds and the resulting equity dilution.
₹100 Cr Rights Issue Approved by Sarda Proteins Ltd
Sarda Proteins Ltd has approved a rights issue to raise up to ₹100 crore, a significant amount considering the company's current net worth of ₹86 crore. The board has approved the Draft Letter of Offer (DLOF) to be filed with SEBI and constituted a committee to oversee the process. This capital infusion is massive relative to the company's recent quarterly revenue of ₹0.65 crore (Mar 2026). Additionally, Non-Executive Director Mr. Gunvantray Jayantilal Zaladi resigned effective August 5, 2026.
Confidence: HIGH
What changedThe company has formally initiated a major capital raising exercise that could more than double its current capital base.
Why it mattersFor a company with very low current revenue (₹0.65 Cr in Mar 2026 quarter), a ₹100 Cr fundraise suggests a potential major business pivot, acquisition, or massive capacity expansion that could fundamentally change its financial profile.
Rights Issue Size: ₹100 CrCurrent Net Worth: ₹86 CrIssue Size vs Net Worth: 116.2%Mar 2026 Q Revenue: ₹0.65 CrFace Value per Share: ₹10
📅 Short termThe stock may experience volatility as the market digests the scale of the potential dilution versus the growth potential of the new capital.
📈 Long termIf the ₹100 Cr is successfully raised and deployed into productive assets, it could lead to a structural re-rating of the business from its current small-scale operations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution for existing shareholders
- Utilization of funds not yet specified
- Management change with director resignation
Key Highlights
Board approved issuance of equity shares on a rights basis for an amount not exceeding ₹100 crore
Proposed fundraise represents approximately 116% of the company's current net worth of ₹86 crore
Equity shares to be issued at a face value of ₹10 each
Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
Draft Letter of Offer (DLOF) approved for filing with SEBI and stock exchanges
👀 What to Watch
Investors should monitor the filing of the Draft Letter of Offer (DLOF) to understand the specific 'Objects of the Issue' and the proposed rights ratio and pricing.
₹100 Cr Rights Issue Approved by Sarda Proteins Ltd
Sarda Proteins has approved a rights issue of up to ₹100 Crore, a massive amount considering the company's current net worth of ₹86 Crore. The Board has approved the Draft Letter of Offer (DLOF) for filing with SEBI and the stock exchanges. This fundraise is highly significant as the company reported a quarterly revenue of only ₹0.65 Crore in March 2026. Additionally, Non-Executive Director Mr. Gunvantray Jayantilal Zaladi has resigned effective August 5, 2026.
Confidence: HIGH
What changedThe company has initiated a major capital raising exercise that could more than double its capital base.
Why it mattersThe scale of the fundraise (₹100 Cr) is disproportionately large compared to the company's current quarterly revenue (₹0.65 Cr), suggesting a potential major business pivot or massive capacity expansion.
Rights Issue Size: ₹100 CroreNet Worth: ₹86 CroreIssue vs Net Worth: 116.27%Quarterly Revenue (Mar 2026): ₹0.65 CroreFace Value: ₹10 per share
📅 Short termThe stock may see volatility as the market digests the potential for massive equity dilution versus the growth prospects of the new capital.
📈 Long termPotentially transformative if the capital is deployed into high-margin edible oil processing; however, the current low revenue base makes execution risk high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution
- Execution risk given the small current scale of operations
- Management change (Director resignation)
Key Highlights
Approved issuance of equity shares on a rights basis for an amount not exceeding ₹10,000 lakhs (₹100 Crore)
Proposed fundraise of ₹100 Crore is approximately 116% of the company's current net worth of ₹86 Crore
Quarterly revenue for the period ending March 2026 was reported at ₹0.65 Crore
Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
Constituted a Rights Issue Committee to oversee the process and finalize the record date
👀 What to Watch
Investors should monitor the Draft Letter of Offer (DLOF) for the rights price, entitlement ratio, and specifically the 'Objects of the Issue' to understand how the ₹100 Crore will be utilized.
Sarda Proteins Ltd FY26 Net Profit at Rs 0.45 Cr; Revenue drops 32% YoY to Rs 16.51 Cr
Sarda Proteins Ltd has issued revised audited financial results for FY26 to correct clerical errors involving interest income and the reclassification of share warrants as equity. For the full year ended March 31, 2026, the company reported a total revenue of Rs 16.51 Cr, representing a 31.7% decline from Rs 24.19 Cr in FY25. Despite the revenue drop, net profit improved to Rs 0.45 Cr from a near-break-even Rs 0.005 Cr in the previous year. The Q4 FY26 performance was bolstered by other income of Rs 24.36 Lakhs, leading to a quarterly profit of Rs 0.686 Cr.
Confidence: HIGH
What changedThe company revised its previously submitted FY26 results to correctly account for interest income and reclassify share warrants as equity capital.
Why it mattersWhile the revision is clerical, the underlying financials show a significant contraction in business scale (revenue down 32%) despite an improvement in absolute profit margins from a very low base.
FY26 Total Revenue: Rs 16.51 CrFY25 Total Revenue: Rs 24.19 CrFY26 Net Profit: Rs 0.45 CrEquity Capital Increase: 520%FY26 Basic EPS: Rs 0.51
📅 Short termThe stock may remain neutral as the revision is non-material to the bottom line, though the revenue decline is a fundamental concern.
📈 Long termThe company's small scale and volatile revenue stream suggest limited structural significance unless it can leverage its debt-free status to expand operations.
⚠ Risk flags
- Significant year-on-year revenue contraction (31.7%)
- High reliance on 'Other Income' for quarterly profitability
- Small absolute scale of operations
Key Highlights
Total Revenue for FY26 declined to Rs 16.51 Cr from Rs 24.19 Cr in FY25.
Net Profit for FY26 stood at Rs 45.44 Lakhs compared to Rs 0.50 Lakhs in FY25.
Paid-up Equity Share Capital increased significantly to Rs 89.76 Lakhs from Rs 17.26 Lakhs due to warrant reclassification.
Q4 FY26 Revenue from operations was minimal at Rs 0.65 Cr compared to Rs 15.26 Cr in the preceding half-year period.
The company reported zero finance costs and zero debt as per the provided financial context.
👀 What to Watch
Investors should monitor the company's ability to stabilize its top-line revenue, which saw a sharp decline this fiscal year. The impact of the warrant-to-equity conversion on future earnings per share (EPS) dilution should also be watched.
Sarda Proteins to consider fundraise via Equity/QIP/Rights Issue on August 05, 2026
Sarda Proteins has scheduled a Board Meeting for August 05, 2026, to evaluate various fund-raising options. The company is considering multiple instruments including equity shares, convertible bonds, debentures, and warrants. Potential routes for this capital infusion include rights issues, private placements, preferential issues, or Qualified Institutions Placements (QIP). As of the announcement on July 31, 2026, the specific quantum of funds to be raised and the intended use of proceeds remain undisclosed.
Confidence: HIGH
What changedThe company has moved from a routine operational phase to actively seeking capital infusion through various equity-linked instruments.
Why it mattersA fundraise is a significant event for a small-cap company in the edible oil sector, as it can either signal aggressive growth plans or a need to strengthen the balance sheet, though it typically involves equity dilution.
Board Meeting Date: August 05, 2026Current Share Price: Rs 97.8Fundraise Amount: not disclosed6-Month Price Return: 32.3%
📅 Short termThe stock price may experience volatility in the days leading up to the August 05 meeting as the market anticipates the size and terms of the fundraise.
📈 Long termThe long-term impact depends on the deployment of funds; capital used for capacity expansion in the edible oil industry could be a structural positive, whereas use for working capital may be neutral.
⚠ Risk flags
- Equity dilution risk for existing shareholders
- Uncertainty regarding the pricing and mode of the fundraise
Key Highlights
Board meeting scheduled for August 05, 2026, to approve fund raising.
Multiple instruments under consideration including equity, convertible bonds, and warrants.
Permissible modes include Rights Issue, Private Placement, and QIP.
Announcement made on July 31, 2026, following a 32.3% price return over the last 6 months.
👀 What to Watch
Investors should watch for the post-meeting disclosure on August 05 to identify the total fundraise amount, the issue price, and whether the capital is intended for debt repayment or capacity expansion.
Sarda Proteins Reports ₹1.66 Cr PAT in Q1 FY27; Pivots to Solar Cell Products Segment
Sarda Proteins reported a sharp turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the year-ago period. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while 'Other Income' saw a massive spike to ₹548.10 Lakhs. Crucially, the company disclosed it now operates solely in the 'Renewable Energy Sector Solar Cell Products' segment, a major shift from its historical edible oil focus. The board also established a new corporate office in Rajkot and appointed an Independent Women Director.
Confidence: HIGH
What changedThe company has turned profitable and officially pivoted its business model from edible oils to the renewable energy/solar cell sector.
Why it mattersThe shift to the solar sector represents a fundamental change in the company's risk-reward profile and growth potential, moving away from low-margin edible oils.
Q1 FY27 Revenue: ₹1,299.30 LakhsQ1 FY27 Net Profit: ₹165.97 LakhsOther Income: ₹548.10 LakhsBasic EPS: ₹1.85Paid up Equity Capital: ₹89.759 Lakhs
📅 Short termThe stock may see positive momentum due to the turnaround from loss to profit and the entry into the high-interest solar sector.
📈 Long termThe long-term outlook depends on the company's ability to scale its new solar cell operations and maintain margins without relying on 'Other Income'.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High reliance on Other Income for current profitability
- Business transition risk into a new industry (Solar)
- Small equity base
Key Highlights
Net Profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26
Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY
Other Income surged to ₹548.10 Lakhs, contributing significantly to the bottom line
Business segment officially transitioned to Renewable Energy Sector Solar Cell Products
Appointment of Ms. Minal Surendra Jain as Independent Women Director for a 5-year term
👀 What to Watch
Investors should monitor the sustainability of the new solar cell business segment and investigate the source of the ₹5.48 Cr 'Other Income' which drove much of this quarter's profit.
₹165.97 Lakhs Net Profit: Sarda Proteins Reports Turnaround in Q1 FY27 Results
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue reached ₹1,847.40 Lakhs, significantly aided by ₹548.10 Lakhs in other income. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director for a 5-year term. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products'.
Confidence: HIGH
What changedThe company has transitioned from a loss-making position to profitability and officially declared its business segment as Renewable Energy/Solar Cell Products while expanding its corporate presence to Gujarat.
Why it mattersThe turnaround and segment shift suggest a major strategic pivot; the establishment of a Gujarat office may indicate a focus on the regional renewable energy hub.
Revenue from Operations (Q1 FY27): ₹1,299.30 LakhsNet Profit (Q1 FY27): ₹165.97 LakhsOther Income: ₹548.10 LakhsBasic EPS: ₹1.85Paid-up Equity Capital: ₹89.759 Lakhs
📅 Short termThe stock may see positive momentum due to the sharp turnaround in profitability and revenue growth reported for the June quarter.
📈 Long termThe structural shift into the Renewable Energy sector is significant; long-term value will depend on the company's ability to generate consistent operating margins in this new segment.
⚠ Risk flags
- High reliance on Other Income for current quarter profitability
- Significant change in business segment (Edible Oil to Solar)
- Small equity base may lead to high volatility
Key Highlights
Reported a Net Profit of ₹165.97 Lakhs in Q1 FY27, reversing a loss of ₹49.34 Lakhs in Q1 FY26.
Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs in the corresponding quarter last year.
Other income surged to ₹548.10 Lakhs, representing nearly 30% of total revenue for the quarter.
Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
👀 What to Watch
Investors should monitor the sustainability of the 'Renewable Energy' segment revenue and investigate the source of the high 'Other Income' which drove the quarterly profit. The shift in business focus from edible oils to solar cell products requires careful tracking of execution in the new sector.
Sarda Proteins Reports ₹1.66 Cr PAT in Q1 FY27; Pivots to Solar Cell Products
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a Net Profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, a sharp recovery from the ₹65 Lakhs reported in the preceding quarter (Q4 FY26). A critical disclosure reveals the company has pivoted its operations to the 'Renewable Energy Sector Solar Cell Products' segment. The board also approved a new corporate office in Rajkot and appointed Ms. Minal Surendra Jain as an Independent Woman Director for a 5-year term.
Confidence: HIGH
What changedThe company returned to profitability, appointed a new Independent Woman Director, and formally transitioned its business focus to the renewable energy sector.
Why it mattersThe pivot to solar cell products is a major strategic shift that could significantly alter the company's growth profile and valuation compared to its legacy edible oil operations.
Revenue (Q1 FY27): ₹1,299.30 LakhsNet Profit (Q1 FY27): ₹165.97 LakhsYoY Revenue Growth: 18.6%EPS (Q1 FY27): ₹1.85Paid-up Equity Capital: ₹89.759 Lakhs
📅 Short termThe stock may see positive momentum due to the turnaround from loss to profit and the entry into the high-interest solar energy sector.
📈 Long termThe long-term outlook depends entirely on the company's ability to execute in the competitive solar cell market, which is a structural shift from its previous industry.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Business pivot risk (Edible Oil to Solar)
- High other expenses (₹643.63 Lakhs in Q1)
- Small equity base leading to potential volatility
Key Highlights
Net Profit turned positive at ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26
Revenue from operations increased 18.6% YoY to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs
Basic and Diluted EPS improved to ₹1.85 from a negative ₹2.86 in the year-ago period
Company officially shifted its business segment to Renewable Energy Sector Solar Cell Products
Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026
👀 What to Watch
Investors should monitor the scalability and margins of the new Solar Cell Products segment, as this represents a complete departure from the company's historical edible oil business.
₹165.97 Lakhs Q1 Profit; Sarda Proteins Reports Turnaround and Segment Shift to Solar Cells
Sarda Proteins reported a net profit of ₹165.97 Lakhs for the quarter ended June 30, 2026, marking a significant turnaround from a loss of ₹49.34 Lakhs in the same period last year. Total revenue reached ₹1,847.40 Lakhs, bolstered by a substantial surge in 'Other Income' to ₹548.10 Lakhs. Notably, the company has identified its primary business segment as 'Renewable Energy Sector Solar Cell Products,' indicating a shift from its historical edible oil focus. The board also approved the establishment of a new corporate office in Rajkot, Gujarat, to support its operations.
Confidence: HIGH
What changedThe company has returned to profitability and officially declared its business segment as Solar Cell Products while expanding its corporate presence to Gujarat.
Why it mattersThe shift to the Renewable Energy sector and the turnaround in profitability suggest a strategic pivot that could fundamentally change the company's growth profile and risk factors.
Q1 Net Profit: ₹165.97 LakhsOther Income: ₹548.10 LakhsRevenue from Operations: ₹1,299.30 LakhsEPS (Basic): ₹1.85Paid-up Equity Capital: ₹89.759 Lakhs
📅 Short termThe stock is likely to see positive sentiment due to the profit turnaround and the announcement of a new corporate office.
📈 Long termThe structural shift into the Solar Cell sector is significant; long-term value will depend on the company's ability to generate consistent operating margins in this new industry.
⚠ Risk flags
- High reliance on 'Other Income' for the current quarter's profitability
- Execution risk associated with the business segment transition
- Limited historical data for the new Solar Cell segment
Key Highlights
Net Profit of ₹165.97 Lakhs in Q1 FY27 compared to a net loss of ₹49.34 Lakhs in Q1 FY26.
Revenue from operations increased by 18.6% YoY to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs.
Other Income spiked to ₹548.10 Lakhs, representing nearly 30% of the total revenue for the quarter.
Earnings Per Share (EPS) improved to ₹1.85 from a negative ₹2.86 in the year-ago quarter.
Establishment of a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
👀 What to Watch
Investors should monitor the sustainability of the 'Other Income' component and seek clarity on the operational scale-up within the newly identified Solar Cell Products segment.
Sarda Proteins Q1 Net Profit at ₹1.66 Cr; Revenue Grows 18.6% YoY to ₹12.99 Cr
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue was further bolstered by a sharp increase in other income to ₹548.10 Lakhs. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products', indicating a shift from its historical edible oil focus.
Confidence: HIGH
What changedThe company returned to profitability in Q1 FY27 and expanded its administrative footprint with a new corporate office in Gujarat while confirming a business focus on solar cell products.
Why it mattersThe turnaround and segment shift suggest a major change in business strategy; however, the high reliance on other income for the bottom line warrants caution regarding core operational strength.
Revenue from Operations: ₹1,299.30 LakhsNet Profit: ₹165.97 LakhsOther Income: ₹548.10 LakhsEPS (Basic): ₹1.85Revenue Growth (YoY): 18.6%
📅 Short termThe stock may see positive sentiment due to the turnaround from a loss to a profit and double-digit revenue growth.
📈 Long termThe structural shift to the renewable energy sector is significant; long-term value will depend on the company's ability to scale this new segment profitably.
⚠ Risk flags
- High reliance on Other Income for current profit
- Business segment shift risk
- Limited historical data on the new solar cell segment
Key Highlights
Net profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26.
Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY.
Other income surged to ₹548.10 Lakhs from just ₹0.08 Lakhs in the previous year's quarter.
Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
👀 What to Watch
Investors should monitor the sustainability of the new 'Renewable Energy Sector Solar Cell Products' segment and investigate the source of the high 'Other Income' which contributed significantly to this quarter's profit.
